C4 Therapeutics Newsroom

Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14

Futu NewsNov 6 21:31 · Ratings

C4 Therapeutics Announced Its Partner Betta Pharmaceuticals Has Dosed The First Patient In The Phase 1 Clinical Trial Of CFT8919, An Orally Bioavailable Allosteric Degrader Of EGFR L858R For Non-small Cell Lung Cancer In Greater China

BenzingaNov 6 20:06

Express News | C4 Therapeutics Announces First Patient Dosed in Cft8919 Clinical Trial

BreakingsNov 6 20:00

C4 Therapeutics to Present Data From the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting

GlobeNewswireNov 5 22:00

Seaport Therapeutics Names Lauren White as Chief Financial Officer

BusinesswireNov 5 20:00

Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating, Maintains Target Price $8

Futu NewsNov 4 21:36 · Ratings

Morgan Stanley Keeps Their Hold Rating on C4 Therapeutics (CCCC)

TipRanksNov 4 21:07 · Ratings

BMO Capital Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $20

Futu NewsNov 1 20:35 · Ratings

Express News | C4 Therapeutics Inc Files for Resale of up to 4.9 Mln Shares of Common Stock by the Selling Stockholder - SEC Filing

BreakingsNov 1 05:28

C4 Therapeutics | 10-Q: Q3 2024 Earnings Report

SECOct 31 19:15 · Announcements

Express News | C4 Therapeutics Q3 EPS USD -0.35 Vs. IBES Estimate USD -0.38

BreakingsOct 31 19:00

Press Release: C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Dow JonesOct 31 19:00

C4 Therapeutics 3Q Loss/Shr 35c >CCCC

Dow JonesOct 31 19:00

Press Release: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Dow JonesOct 16 04:01

Express News | C4 Therapeutics Appoints Paige Mahaney, Ph.d., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.d.

BreakingsOct 16 04:01

Express News | C4 Therapeutics Announces Presentations and Participation in 7TH Annual Targeted Protein Degradation & Induced Proximity Summit

BreakingsOct 9 19:00

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

C4 TherapeuticsOct 9 12:00

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Business Is Trailing The Industry But Its Shares Aren't

Simply Wall StOct 3 21:28

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireOct 1 04:01

Express News | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

BreakingsOct 1 04:01